We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters to the Editor |

Sinonasal Disease and Nasal Saline

Baran Acar, MD; Hayriye Karabulut, MD
Arch Otolaryngol Head Neck Surg. 2007;133(6):625. doi:10.1001/archotol.133.6.625-a.
Text Size: A A A
Published online


We read with interest the article by Cimmino et al1 in the December 2005 issue of the Archives. The authors concluded that dornase alfa is superior to placebo (saline in this study) for the treatment of patients with cystic fibrosis and nasal symptoms. However, we think that the use of isotonic saline solution as placebo is inappropriate. It is well known that nasal washing with saline solution facilitates nasal drainage and cleans the airway of any postnasal discharge; it can be effective when applied appropriately (5 dropperfuls in each nostril at least 4 times a day).2,3 Saline solution irrigation has been found to reduce inflammatory mediators (histamine, prostaglandin D2, and leukotriene C4) and allergens in nasal secretions.4 Therefore, nasal saline washing with the correct technique is a cheap and effective method for treating inflammatory conditions of the upper respiratory tract such as the common cold, acute and chronic sinusitis, and chronic rhinitis.2,4 Given all these factors, we believe that nasal saline washing with the correct technique can be as effective as treatment with dornase alfa; therefore, it should not be used as a placebo in this type of study.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview





June 1, 2007
Valeria Raia, MD; Angela Sepe, MD; Mariano Cimmino, MD; Massimiliano Nardone, MD; Matteo Cavaliere, MD; Angela Plantulli, MD; Giuseppina Mazzarella, MD
Arch Otolaryngol Head Neck Surg. 2007;133(6):625. doi:10.1001/archotol.133.6.625-b.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...